

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Currently Amended) A method for preventing or ameliorating chemotherapy~~cytotoxic agent~~-induced thrombocytopenia, comprising administering to a patient in need thereof an effective amount of a thiol-based compound or composition ~~prior to, wherein said thiol-based compound or composition is selected from the group consisting of sodium thiosulfate and NAC concurrently with; or following the administration of a chemotherapeutic agent or chemotherapeutic agents~~myelosuppressive chemotherapy.

2. (Original) The method according to claim 1 wherein the patient in need thereof does not receive a blood brain barrier disruption procedure.

3. (Original) The method according to claim 1 wherein the thiol-based compound is administered intravenously.

4.-11. (Canceled)

12. (Currently Amended) The method according to claim ~~7-11~~7-1 wherein the thiol-based compound is administered ~~at least 6~~about four hours following the completion of the administration of the chemotherapeutic agent ~~or at least one of the chemotherapeutic agents~~myelosuppressive chemotherapy.

13. (Currently Amended) The method according to claim ~~7-11~~7-1 wherein the thiol-based compound is administered ~~hour~~in two doses, the first dose at about four hours

following the completion of the administration of the myelosuppressive chemotherapy and the second dose at about 8 hours following the completion of the administration of the chemotherapeutic agent or at least one of the chemotherapeutic agents myelosuppressive chemotherapy.

14. (Canceled)

15. (Original) The method according to claim 1 wherein the thiol-based compound is sodium thiosulfate.

16. (Original) The method according to claim 1 wherein the thiol-based compound is N-acetylcysteine.

17. (Original) The method according to claim 1 wherein the thiol-based composition comprises sodium thiosulfate and N-acetylcysteine.

18. (Currently Amended) The method according to claim 1 wherein the myelosuppressive chemotherapy chemotherapeutic agent is comprises an alkylating agent.

19. (Original) The method according to claim 17 wherein the alkylating agent is a platinum-containing alkylating agent.

20. (Currently Amended) The method according to claim 18 wherein the platinum-containing alkylating agent is selected from the group consisting of cisplatin, and carboplatin and oxyplatin.

21. (Currently Amended) The method according to claim 1 wherein the ~~chemotherapeutic agents~~ myelosuppressive chemotherapy comprises cyclophosphamide, carboplatin and etoposide phosphate.

22. (Original) The method according to claim 1 wherein the patient in need thereof has a tumor in the head or neck.

23. (Original) The method according to claim 1 wherein the patient in need thereof is a human.

24. (Original) The method according to claim 23 wherein the thiol-based compound is sodium thiosulfate.

25. (Currently Amended) The method according to claim 24 wherein the myelosuppressive chemotherapy ~~chemotherapeutic agents~~ comprises cyclophosphamide, carboplatin and etoposide phosphate.

26. (Currently Amended) The method according to claim 24 wherein the sodium thiosulfate is administered at a dosage of ~~±5~~ 16-20 grams/m<sup>2</sup>.

27. (Currently Amended) The method according to claim 26 wherein the sodium thiosulfate is administered intravenously.

28. (Currently Amended) The method according to claim 27 wherein the sodium thiosulfate is administered at least 4 hours following the administration of the myelosuppressive chemotherapy ~~chemotherapeutic agent or at least one of the chemotherapeutic agents~~.

29. (Canceled)

30. (New) The method according to claim 1 wherein the myelosuppressive chemotherapy comprises platinum chemotherapy.